Abstract
In last month's issue 1 Matthew Scharff and his colleagues discussed recent improvements in the technique of making monoclonal antibodies by cell fusion. However, not all the monoclonal antibodies generated by hybridoma technology have all of the properties required for a particular task. This second part of a two-part review deals with ways in which these first-generation reagents can be improved by identifying somatic-cell mutants with the desired properties or by engineering new and even novel molecules using recombinant DNA technology.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
